Sitagliptin phosphate: isolation and identification of two degradation products formed under acid conditions and determination of in vitro cytotoxicity

Alini Dall Cortivo  Lange; Diogo Miron; Le´tícia Lenz Sfair; Elfrides Eva Scherman Schapoval

doi:10.22456/2527-2616.133259

Authors

Alini Dall Cortivo Lange Programa de Pós-graduação em Ciências Farmacêuticas - Universidade Federal do Rio Grande do Sul
Diogo Miron Programa de Pós-graduação em Ciências Farmacêuticas - Universidade Federal do Rio Grande do Sul
Le´tícia Lenz Sfair Programa de Pós-graduação em Ciências Farmacêuticas - Universidade Federal do Rio Grande do Sul
Elfrides Eva Scherman Schapoval Programa de Pós-graduação em Ciências Farmacêuticas - Universidade Federal do Rio Grande do Sul

DOI:

https://doi.org/10.22456/2527-2616.133259

Keywords:

Sitagliptin phosphate, Indicating-stability method, Degradation product, Cytotoxicity

Abstract

Sitagliptin phosphate (STG), used for the treatment of type 2 diabetes, is a drug that belongs to a new class called inhibitors of dipeptidyl peptidase IV (DPPIV). It is known to be the first agent of the class approved by the FDA. Currently, many studies describe the determination of STG in plasma and pharmaceutical formulations but there are few studies on the drug stability. Forced degradation studies were conducted to isolate and identify the main degradation products. It was possible to observe the formation of two degradation products (DP1 and DP2) in hydrochloric 2.5M acid at 60°C. The structural characterization by UPLC-UV/MS of the degradation products was important to understand the degradation mechanism of STG under acid conditions. Purified degradation products were tested in vitro for cytotoxicity with a mononuclear cell assay. No cytotoxicity was observed at the concentration range of 10.0–250.0 µg.mL^-1. The structural characterization of the degradation products was important to understand the degradation mechanism of STG under acid conditions. Today, there are some resolutions and consensus, national and international, which show the importance of knowing and identifying the degradation products and also to evaluate the cytotoxic potential of these molecules.

Downloads

Download data is not yet available.

References

Bloomgarden Z. Diabetes treatment: the coming paradigm shift, J. Diabetes 2012; 4:315-317.

Zeng L, Ding YJ, Zhang GC, Song HR, Hu WH. A practical synthesis of trifluorophenyl R-amino acid: The key precursor for the new anti-diabetic drug sitagliptin. Chin Chem Letters 2009; 20:1397-1399.

Thornberry JNA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Prac & Res Clin Endoc & Metab. 2009; 23:479-486.

Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12:87- 100.

Ravanello A, Schreiner LD, Marcolino AIP, Codevilla CF, Horn AAI, Rolim CMB. A Simple StabilityIndicating LC-UV Method to Assay Sitagliptin Phosphate in Tablets. Curr Anal Chem. 2012; 8(4):569-573.

Vincent SH, Reed JR, Bergman AJ, Elmore CS, B. Zhu B, Xu S, et al. Metabolism and excretion of dipeptidase 4 inhibitor (14C) sitagliptin in humans, Drug Metab Dispos. 2007; 35:533-538.

Zeng W, Musson DG, Fisher AL, Chen L, Schwartz MS, Woolf EJ. Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tendem mass spectrophotometry, J Pharm Biomed Anal. 2008; 46:534-542.

Nirogi R, Kandikere V, Mudigonda K, Komarneni P, Aleti R, Boggavarapu R. Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid extraction. Biomed Chromatogr. 2008; 22:214-222.

Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ. Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs. Drug Metab Dispos. 2007; 35:525-532.

Pathade P, Imran M, Bairagi V, Ahire Y. Development and Validation of Stability Indicating UV Spectrophotometric Method for the Estimation of Sitagliptin Phosphate in Bulk and Tablet Dosage Form. J Pharm Res. 2011; 4(3):871-873.

Sekaran CB, Rani AP. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor, sitagliptin, in its pharmaceutical preparations. Ecl Quím. 2010; 35(3):45-53.

Shokouhi S, Sohrabi MR. Net analyte signal and radial basis function neural network for development spectrophotometry method for the simultaneous determination of metformin and sitagliptin in antidiabetic commercial tablet. Intern J Light Electron Optic. 2021; 243:167518.

El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product. Talanta. 2011; 85(1):673-680.

El-Bagary RI, Elkady EF, Ayoub BM. Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product. Intern J of Biom Sci. 2011; 7(1):62-69.

Li YS, Tseng WL, Lu CY. Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry. Talanta. 2020; 218:121143.

Gumieniczeka A, Berecka A, Mroczek T, Wojtanowski K, Dabrowska K, Stepién K. Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods. J Pharm Biom Anal 2019; 164:789-807.

Krakko D, Illés A, Domján A, Demeter A, Dóbé S, Zaráy G. UV and UV irradiation of sitagliptin in ultrapure water and WWTP effluent: Kinetics, transformation products and degradation pathway. Chemosphere. 2022; 288:132393.

Pasquini B, Gotti R, Villar-Navarroc M, Dousa M, Renai L, Del Bubba M, Orlandini S, et al. Analytical quality by design in the development of a solventmodified micellar electrokinetic chromatography method for the determination of sitagliptin and its related compounds. J Pharm Biom Anal. 2021; 202:114163.

Lange ADC, Gasperin FT, Passos CS, Todeschini V, Volpato NM, Schapoval EES. Stability-Indicating LC assay with determination of system suitability limits by a robustness test for sitagliptin in tablets and assessment of cytotoxicity for degradation products. Curr Pharm Anal. 2012; 8:360-367.

Lange ADC, Gasperin FT, Barth AB, Todeschini V, Volpato NM, Schapoval EES. Application of factorial design and study of photodegradation kinetics for the determination of sitagliptin by capillary electrophoresis. Curr Anal Chem. 2011; 8:116-123.

Martinez V, Corsini E, Mitjans M, Pinazo A, Vinardell MP. Evaluation of eye and skin irritation of arginine-derivative surfactants using different in vitro endpoints as alternatives to the in vivo assays. Toxicol Lett. 2006; 164:259-267